Leukoplakia of vagina
ICD-10 N89.4 · ICD-11 GA14.5

Treatment of Leukoplakia of Vagina in Vulvar Lichen Sclerosus When First-Line Corticosteroid Therapy Has Failed

This protocol applies to leukoplakia of vagina in patients with vulvar lichen sclerosus (VLS) who have not achieved adequate symptom control with first-line therapy. It defines the clinical approach taken once standard corticosteroid-based management has been tried and has not met its goals.

Clinical Scenario — Vulvar Lichen Sclerosus

Vulvar lichen sclerosus is the underlying condition in this presentation. Vulvar lichen sclerosus is one of the non-neoplastic epithelial disorders of the vulva generally referred to as vulvar leukoplakia. This protocol targets the subset of patients with VLS whose condition has not responded to first-line management.

Why This Protocol — Prior Treatment Did Not Work

First-line management of VLS encompasses minimising irritants, soap substitution, emollient moisturisation, treatment of co-infections, and a structured course of topical corticosteroids (clobetasol propionate). That first-line approach aims to achieve control and resolution of genital itching and complete recovery of the vulvar skin. This protocol applies when that course has not met those goals.

Next-Step Approach (Partial — Full Protocol Below)

For patients refractory to corticosteroid treatment, the protocol calls for a topical calcineurin inhibitor as the alternative agent. The clinical goal is resolution of genital itching. The complete regimen — specifying which agent, management considerations, and treatment duration guidance — is contained in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.5114/pm.2020.99570

  • Two non-neoplastic epithelial disorders of the vulva – vulvar LS (VLS) and squamous cell hyperplasia of the vulva (SCHV) – are generally referred to as vulvar leukoplakia.
  • If VLS treatment fails, there are some alternative, less popular options such as the use of topical calcineurin inhibitors (TCIs).
  • Pimecrolimus and tacrolimus are used.
  • The described dose of tacrolimus ointment is twice daily until symptoms disappear, and the course of treatment should not be too long.
  • It should only be used in patients refractory to corticosteroid treatment.
View source ↗